Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin) (CONCERT)

Roche

Status: Completed

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: Concomitant Bevacizumab; Other: Observational Chemotherapy

Study type: Observational

Funder types: Industry

Identifiers

NCT02612077

ML21696

Details and patient eligibility

About

This is a longitudinal, multicenter, prospective, pharmacoepidemiological study to evaluate progression free survival (PFS) in a real-life setting in participants with metastatic colorectal cancer (mCRC) starting chemotherapy combined with bevacizumab.

Enrollment: 765 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Having colon or rectal metastatic adenocarcinoma, for which the physician decided during the inclusion visit to start a treatment with bevacizumab combined with a 1st, 2nd or 3rd line chemotherapy
• Having received oral and written information about the survey and not objecting to having his/her data computerized

Exclusion criteria

• Participating in a clinical trial assessing an anticancer treatment

Trial design

765 participants in 1 patient group

Observational Chemotherapy/Bevacizumab

Description:

Observed patients receiving chemotherapy with concomitant bevacizumab

Treatment:

Other: Observational Chemotherapy

Drug: Concomitant Bevacizumab